Qlucore expanding its collaboration in precision diagnostics with Lund University with the aim of developing solutions for improved diagnostics of more forms of blood cancer. Combining the software expertise of Qlucore with the cancer diagnostics expertise of Lund University, the collaboration aims to develop and evaluate so-called classification models for improved diagnostics of two different forms of blood cancer, acute lymphoblastic and acute myeloid leukemia. The classification models are then used together with the AI-based products Qlucore Diagnostics and Qlucore Insights.

The goal is to support more customized cancer treatment and to obtain CE marking for Qlucore Diagnostics. Precision diagnostics for cancer has developed rapidly in recent years, driven by so-called next generation sequencing (NGS). Until now, the focus has been on mutations and variants in the genetic code at the DNA level, which have been used for both patient classification and cancer treatment decisions.

For some time now, interest has increased in techniques based on measurements of gene activity levels as this provides improved opportunities to determine which diagnosis a patient receives, and which treatment is most appropriate.